Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | MEN1 | O00255 | 5/20 | 0.36 |
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | GLA | P06280 | 3/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | DRD2 | P14416 | 3/20 | 0.33 |
| ▸ | DRD1 | P21728 | 3/20 | 0.33 |
| ▸ | DRD4 | P21917 | 3/20 | 0.33 |
| ▸ | DRD5 | P21918 | 3/20 | 0.33 |
| ▸ | DRD3 | P35462 | 3/20 | 0.33 |
| ▸ | MAOA | P21397 | 2/20 | 0.32 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23551266 | 0.81 | KMT2A (0.42) | MAPTKDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL18368356 | 0.79 | KMT2A (0.40) | MAPTKDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL18378881 | 0.77 | KMT2A (0.38) | MAPTKDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL25121974 | 0.76 | ALDH1A1 (0.37) | MAPTKDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL18379188 | 0.75 | KDM4E (0.44) | MAPTKDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL24733006 | 0.75 | MAOA (0.38) | MAPTKDM4EKMT2AALDH1A1MEN1 | |
| SCHEMBL18368357 | 0.74 | EGFR (0.38) | — | |
| SCHEMBL25478156 | 0.72 | MAPT (0.39) | MAPTKDM4EALDH1A1HPGDGAA | |
| SCHEMBL2607685 | 0.72 | MAPT (0.42) | MAPTKDM4EALDH1A1HPGDGAA | |
| SCHEMBL14832181 | 0.71 | CYP2C19 (0.40) | MAPTKDM4EKMT2AALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827662-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-08-10 | — | — | US | disclosed |
| US-20230110648-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| US-20230002407-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2023-01-05 | — | — | US | disclosed |
| US-11066414-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-10947259-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20210061831-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2021-03-04 | — | — | US | disclosed |
| US-20200392170-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2020-12-17 | — | — | US | disclosed |
| US-20200123172-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2020-04-23 | — | — | US | disclosed |
| US-20190248807-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. (US) | 2019-08-15 | — | — | US | disclosed |
| US-9878995-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-9878995-B2 | Cot modulators and methods of use thereof | GILEAD SCIENCES, INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170152240-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-06-01 | — | — | US | disclosed |
| US-20170152240-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-06-01 | — | — | US | disclosed |
| US-20170008905-A1 | COT MODULATORS AND METHODS OF USE THEREOF | GILEAD SCIENCES, INC. | 2017-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392170-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | MAPT 4689/4885KDM4E 1288/4885KMT2A 1644/4885 |
| US-10947259-B2 | Cot modulators and methods of use thereof | BRDT, THRB, HCCS | MAPT 4689/4885KDM4E 1288/4885KMT2A 1644/4885 |
| US-20230002407-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | MAPT 4689/4885KDM4E 1288/4885KMT2A 1644/4885 |
| US-20200123172-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | MAPT 4689/4885KDM4E 1288/4885KMT2A 1644/4885 |
| US-20190248807-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | MAPT 4689/4885KDM4E 1288/4885KMT2A 1644/4885 |
| US-20170152240-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | MAPT 4689/4885KDM4E 1288/4885KMT2A 1644/4885 |
| US-20230110648-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | MAPT 2356/4885KDM4E 1445/4885KMT2A 2641/4885 |
| US-11066414-B2 | Cot modulators and methods of use thereof | BRDT, THRB, HCCS | MAPT 4689/4885KDM4E 1288/4885KMT2A 1644/4885 |
| US-20170008905-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | MAPT 4689/4885KDM4E 1288/4885KMT2A 1644/4885 |
| US-20210061831-A1 | COT MODULATORS AND METHODS OF USE THEREOF | BRDT, THRB, HCCS | MAPT 4689/4885KDM4E 1288/4885KMT2A 1644/4885 |
| US-20230250060-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | MAPT 3027/4885KDM4E 3761/4885KMT2A 3772/4885 |
| US-20230250088-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | MAPT 3076/4885KDM4E 3667/4885KMT2A 3713/4885 |
| US-11827662-B2 | Cot modulators and methods of use thereof | BRDT, THRB, HCCS | MAPT 4689/4885KDM4E 1288/4885KMT2A 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.